en
Scientific article
Open access
English

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

Published inAnnals of the rheumatic diseases, vol. 75, no. 10, p. 1806-1812
Publication date2016
Abstract

Compare changes in lipids and lipid-associated cardiovascular (CV) risk markers in patients with rheumatoid arthritis (RA) treated with tocilizumab or adalimumab.

Citation (ISO format)
GABAY, Cem et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. In: Annals of the rheumatic diseases, 2016, vol. 75, n° 10, p. 1806–1812. doi: 10.1136/annrheumdis-2015-207872
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0003-4967
437views
184downloads

Technical informations

Creation08/31/2016 4:48:00 PM
First validation08/31/2016 4:48:00 PM
Update time03/15/2023 12:47:57 AM
Status update03/15/2023 12:47:57 AM
Last indexation01/16/2024 9:56:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack